CoChat
Sign Up
Cited by 327

American Cancer Society Colorectal Cancer Survivorship Care Guidelines

El‐Shami, Khaled, Oeffinger, Kevin C., Erb, Nicole L., Willis, Anne, Bretsch, Jennifer K., Pratt‐Chapman, Mandi L., Cannady, Rachel S., Wong, Sandra L. +6 more·2015·CA: A Cancer Journal for Clinicians
DOI 10.3322/caac.21286PMC PMC5385892
Open this paper in CoChat — free account

Abstract

Answer questions and earn CME/CNE Colorectal cancer (CRC) is the third most common cancer and third leading cause of cancer death in both men and women and second leading cause of cancer death when men and women are combined in the United States (US). Almost two‐thirds of CRC survivors are living 5 years after diagnosis. Considering the recent decline in both incidence and mortality, the prevalence of CRC survivors is likely to increase dramatically over the coming decades with the increase in rates of CRC screening, further advances in early detection and treatment and the aging and growth of the US population. Survivors are at risk for a CRC recurrence, a new primary CRC, other cancers, as well as both short‐term and long‐term adverse effects of the CRC and the modalities used to treat it. CRC survivors may also have psychological, reproductive, genetic, social, and employment concerns after treatment. Communication and coordination of care between the treating oncologist and the primary care clinician is critical to effectively and efficiently manage the long‐term care of CRC survivors. The guidelines in this article are intended to assist primary care clinicians in delivering risk‐based health care for CRC survivors who have completed active therapy. CA Cancer J Clin 2015;65:427–455 . © 2015 American Cancer Society.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3322/caac.21286

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A multi-target stool test comprising DNA markers and FIT has been approved by FDA for CRC screening, incorporated into guidelines, and become available.

    “A multi-target stool test, comprising a panel of DNA markers and FIT [9–11], has been approved by the Food and Drug Administration (FDA) for CRC screening, been incorporated into CRC screening guidelines by the American Cancer Society and United States Preventive Services Task Force [14, 15], and become available to patients.”

    From Novel Approach to Fecal Occult Blood Testing by Assay of Erythrocyte-Specific microRNA Markers (2017) · cites this paper as [15]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 130

  1. [1]Institute of Medicine From cancer patient to cancer survivor: lost in transition 2005 Washington, DC National Academies Press
  2. [4]Institute of Medicine Cancer care for the whole patient: meeting psychosocial health needs 2007 Washington, DC National Academies Press 20669419
  3. [5]Mullan F Seasons of survival: reflections of a physician with cancer N Engl J Med 1985 25 313 4 270 273 4010738
  4. [6]McCabe MS Bhatia S Oeffinger KC American Society of Clinical Oncology statement: achieving high-quality cancer survivorship care J Clin Oncol 2013 31 5 631 640 23295805 PMC4878049
  5. [7]National Comprehensive Cancer Network I NCCN clinical practice guidelines in oncology: colon cancer, version 2.2015 19755046
  6. [8]National Comprehensive Cancer Network I NCCN clinical practice guidelines in oncology: rectal cancer, version 2.2015 19755047
  7. [9]National Comprehensive Cancer Network I NCCN clinical practice guidelines in oncology: survivorship, version 1.2015 PMC5865602 28874599
  8. [10]Bower JE Bak K Berger A Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical oncology clinical practice guideline adaptation J Clin Oncol 2014 10 32 17 1840 1850 24733803 PMC4039870
  9. [11]Andersen BL DeRubeis RJ Berman BS Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation J Clin Oncol 2014 32 15 1605 1619 24733793 PMC4090422
  10. [12]Hershman DL Lacchetti C Dworkin RH Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline J Clin Oncol 2014 20 32 18 1941 1967 24733808
  11. [13]Loren AW Mangu PB Beck LN Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update J Clin Oncol 2013 31 19 2500 2510 23715580 PMC5321083
  12. [14]Smith TJ Temin S Alesi ER American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care J Clin Oncol 2012 30 8 880 887 22312101
  13. [15]Cowens-Alvarado R Sharpe K Pratt-Chapman M Advancing survivorship care through the National Cancer Survivorship Resource Center: developing American Cancer Society guidelines for primary care providers CA Cancer J Clin 2013 63 3 147 150 23512728
  14. [16]Siegel RL Miller KD Jemal A Cancer statistics, 2015 CA Cancer J Clin 2015 65 1 5 29 25559415
  15. [17]Howlader NNA Krapcho M SEER Cancer Statistics Review, 1975–2012
  16. [18]Siegel R Desantis C Jemal A Colorectal cancer statistics, 2014 CA Cancer J Clin 2014 64 2 104 117 24639052
  17. [19]DeSantis CE Lin CC Mariotto AB Cancer treatment and survivorship statistics, 2014 CA Cancer J Clin 2014 64 4 252 271 24890451
  18. [21]Skolarus TA Wolf AM Erb NL American Cancer Society prostate cancer survivorship care guidelines CA Cancer J Clin 2014 64 4 225 249 24916760
  19. [22]Brawley O Byers T Chen A New American Cancer Society process for creating trustworthy cancer screening guidelines JAMA 2011 306 22 2495 2499 22166609
  20. [23]Institute of Medicine Clinical Practice Guidelines We Can Trust 2011 Washington, DC National Academies Press
  21. [24]Meyerhardt JA Mangu PB Flynn PJ Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement J Clin Oncol 2013 31 35 4465 4470 24220554
  22. [25]Rose J Augestad KM Cooper GS Colorectal cancer surveillance: what's new and what's next World J Gastroenterol 2014 20 8 1887 1897 24587668 PMC3934459
  23. [26]Sargent DJ Patiyil S Yothers G End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group J Clin Oncol 2007 25 29 4569 4574 17876008
  24. [27]Smith RA Manassaram-Baptiste D Brooks D Cancer screening in the United States, 2015: a review of current American cancer society guidelines and current issues in cancer screening CA Cancer J Clin 2015 65 1 30 54 25581023
  25. [29]Wolf AM Wender RC Etzioni RB American Cancer Society guideline for the early detection of prostate cancer: update 2010 CA Cancer J Clin 2010 60 2 70 98 20200110
  26. [30]Koornstra JJ Mourits MJ Sijmons RH Leliveld AM Hollema H Kleibeuker JH Management of extracolonic tumours in patients with Lynch syndrome Lancet Oncol 2009 10 4 400 408 19341971
  27. [31]Barrow E Robinson L Alduaij W Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations Clin. Genet 2009 75 2 141 149 19215248
  28. [32]Dijkhuizen FP Mol BW Brolmann HA Heintz AP The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis Cancer 2000 89 8 1765 1772 11042572
  29. [33]Breijer MC Peeters JA Opmeer BC Capacity of endometrial thickness measurement to diagnose endometrial carcinoma in asymptomatic postmenopausal women: a systematic review and meta-analysis Ultrasound Obstet Gynecol 2012 40 6 621 629 23001905
  30. [34]Schmeler KM Lynch HT Chen LM Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome N Engl J Med 2006 354 3 261 269 16421367
  31. [36]Lindor NM Petersen GM Hadley DW Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review JAMA 2006 296 12 1507 1517 17003399
  32. [37]Ramsey SD Berry K Moinpour C Giedzinska A Andersen MR Quality of life in long term survivors of colorectal cancer Amer J Gastroenterol 2002 97 5 1228 1234 12017152
  33. [38]Emmertsen KJ Laurberg S Rectal Cancer Function Study G Impact of bowel dysfunction on quality of life after sphincter-preserving resection for rectal cancer The Br J Surg 2013 100 10 1377 1387 23939851
  34. [39]Guren MG Eriksen MT Wiig JN Quality of life and functional outcome following anterior or abdominoperineal resection for rectal cancer Eur J Surg Oncol 2005 31 7 735 742 16180267
  35. [40]Braendengen M Tveit KM Bruheim K Cvancarova M Berglund A Glimelius B Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: results from a randomized Phase III study Int J Radiat Oncol Biol Phys 2011 81 4 1017 1024 20932687
  36. [41]Lange MM Martz JE Ramdeen B Long-term results of rectal cancer surgery with a systematical operative approach Ann Surg Oncol 2013 20 6 1806 1815 23536052
  37. [42]Peeters KC van de Velde CJ Leer JW Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients--a Dutch colorectal cancer group study J Clin Oncol 2005 23 25 6199 6206 16135487
  38. [43]Gami BHK Blake P How patients manage gastrointestinal symptoms after pelvic radiotherapy Aliment Pharmacol Ther 2003 18 10 987 994 14616164
  39. [44]Khan NF Mant D Carpenter L Forman D Rose PW Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study Brit J Cancer 2011 105 Suppl 1 S29 S37 22048030 PMC3251947
  40. [45]Jensen SA Sorensen JB 5-fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity Cancer Chemother Pharmacol 2012 69 1 57 64 21603868
  41. [46]Polk A Vistisen K Vaage-Nilsen M Nielsen DL A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity BMC Pharmacol Toxicol 2014 15 47 25186061 PMC4170068
  42. [47]Polk A Vaage-Nilsen M Vistisen K Nielsen DL Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors Cancer Treat Rev 2013 39 8 974 984 23582737
  43. [49]Giovannucci E Ascherio A Rimm EB Colditz GA Stampfer MJ Willett WC Physical activity, obesity, and risk for colon cancer and adenoma in men Ann Intern Med 1995 122 5 327 334 7847643
  44. [50]Hawkes AL Lynch BM Owen N Aitken JF Lifestyle factors associated concurrently and prospectively with co-morbid cardiovascular disease in a population-based cohort of colorectal cancer survivors Eur J Cancer 2011 47 2 267 276 21074408
  45. [51]Jones LW Haykowsky MJ Swartz JJ Douglas PS Mackey JR Early breast cancer therapy and cardiovascular injury J Am Coll Cardiol 2007 50 15 1435 1441 17919562
  46. [52]Wefel JS Kesler SR Noll KR Schagen SB Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults CA Cancer J Clin 2015 65 2 123 138 25483452 PMC4355212
  47. [53]Jean-Pierre P Winters PC Ahles TA Prevalence of self-reported memory problems in adult cancer survivors: a national cross-sectional study J Clin Oncol 2012 8 1 30 34 PMC3266313 22548008
  48. [54]Jansen L Hoffmeister M Chang-Claude J Koch M Brenner H Arndt V Age-specific administration of chemotherapy and long-term quality of life in stage II and III colorectal cancer patients: a population-based prospective cohort Oncologist 2011 16 12 1741 1751 22101506 PMC3248773
  49. [55]Tannock IF Ahles TA Ganz PA Van Dam FS Cognitive impairment associated with chemotherapy for cancer: report of a workshop J Clin Oncol 2004 22 11 2233 2239 15169812
  50. [57]Boyes AW Girgis A Zucca AC Lecathelinais C Anxiety and depression among long-term survivors of cancer in Australia: results of a population-based survey. Comment Med J Aust 2009 191 5 295 19839084
  51. [60]Denlinger CS Barsevick AM The challenges of colorectal cancer survivorship J Natl Compr Cancer Netw 2009 7 8 883 893 quiz 894 PMC3110673 19755048
  52. [61]Ross L Abild-Nielsen AG Thomsen BL Karlsen RV Boesen EH Johansen C Quality of life of Danish colorectal cancer patients with and without a stoma Support Care Cancer 2007 15 5 505 513 17103196
  53. [62]National Comprehensive Cancer Network I NCCN clinical practice guidelines: distress management, version 2.2014 PMC6907687 31590149
  54. [63]Patel D Sharpe L Thewes B Bell ML Clarke S Using the Distress Thermometer and Hospital Anxiety and Depression Scale to screen for psychosocial morbidity in patients diagnosed with colorectal cancer J Affect Disord 2011 131 1–3 412 416 21130501
  55. [64]Campbell HS Sanson-Fisher R Turner D Hayward L Wang XS Taylor-Brown J Psychometric properties of cancer survivors' unmet needs survey Support Care Cancer 2010 19 2 221 230 20099001
  56. [65]Campbell HS Hall AE Sanson-Fisher RW Barker D Turner D Taylor-Brown J Development and validation of the Short-Form Survivor Unmet Needs Survey (SF-SUNS) Support Care Cancer 2014 22 4 1071 1079 24292016
  57. [68]Medeiros M Oshima CT Forones NM Depression and anxiety in colorectal cancer patients J Gastrointest Cancer 2010 41 3 179 184 20180047
  58. [72]Krebber AM Buffart LM Kleijn G Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments Psychooncology 2014 23 2 121 130 24105788 PMC4282549
  59. [73]Kuchler T Bestmann B Rappat S Henne-Bruns D Wood-Dauphinee S Impact of psychotherapeutic support for patients with gastrointestinal cancer undergoing surgery: 10-year survival results of a randomized trial J Clin Oncol 2007 25 19 2702 2708 17602075
  60. [74]Sharma A Walker LG Monson JR Baseline quality of life factors predict long term survival after elective resection for colorectal cancer Intl J Surg Oncol 2013 2013 269510 PMC3863491 24369498
  61. [75]Mishra SISR Geigle PM Exercise interventions on health-related quality of life for cancer survivors Cochrane Database Syst Rev 2012 8 CD007566 PMC7387117 22895961
  62. [77]Wang XS Zhao F Fisch MJ Prevalence and characteristics of moderate to severe fatigue: a multicenter study in cancer patients and survivors Cancer 2014 120 3 425 432 24436136 PMC3949157
  63. [78]Yanez B Pearman T Lis CG Beaumont JL Cella D The FACT-G7: a rapid version of the functional assessment of cancer therapy-general (FACT-G) for monitoring symptoms and concerns in oncology practice and research Ann Oncol 2013 24 4 1073 1078 23136235
  64. [79]Wang XS Cleeland CS Mendoza TR Impact of cultural and linguistic factors on symptom reporting by patients with cancer J Natl Cancer Inst 2010 102 10 732 738 20348233 PMC2873184
  65. [80]Minton O Strasser F Radbruch L Stone P Identification of factors associated with fatigue in advanced cancer: a subset analysis of the European palliative care research collaborative computerized symptom assessment data set J Pain Symptom Manage 2012 43 2 226 235 21839608
  66. [81]Kuhnt S Ernst J Singer S Fatigue in cancer survivors--prevalence and correlates Onkologie 2009 6 32 6 312 317 19521117
  67. [82]Mendoza TR Wang XS Cleeland CS The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory Cancer 1999 85 5 1186 1196 10091805
  68. [83]Servaes P Gielissen MF Verhagen S Bleijenberg G The course of severe fatigue in disease-free breast cancer patients: a longitudinal study Psychooncology 2007 16 9 787 795 17086555
  69. [84]Pachman DR Barton DL Swetz KM Loprinzi CL Troublesome symptoms in cancer survivors: fatigue, insomnia, neuropathy, and pain J Clin Oncol 2012 30 30 3687 3696 23008320
  70. [85]Mitchell SA Cancer-related fatigue: state of the science PM & R 2010 2 5 364 383 20656618
  71. [86]Mitchell SA Beck SL Hood LE Moore K Tanner ER Putting evidence into practice: evidence-based interventions for fatigue during and following cancer and its treatment Clin J Oncol Nurs 2007 11 1 99 113 17441401
  72. [88]Butt Z Wagner LI Beaumont JL Use of a single-item screening tool to detect clinically significant fatigue, pain, distress, and anorexia in ambulatory cancer practice J Pain Symptom Manage 2008 35 1 20 30 17959345
  73. [89]Cleeland CS Mendoza TR Wang XS Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory Cancer 2000 89 7 1634 1646 11013380
  74. [91]Hann DM Jacobsen PB Azzarello LM Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory Quality of life research: an international journal of quality of life aspects of treatment, care and rehabilitation 1998 5 7 4 301 310 9610214
  75. [92]Stein KD Martin SC Hann DM Jacobsen PB A multidimensional measure of fatigue for use with cancer patients Cancer practice 1998 May-Jun 6 3 143 152 9652245
  76. [93]Chambers SK Meng X Youl P Aitken J Dunn J Baade P A five-year prospective study of quality of life after colorectal cancer Qual Life Res 2012 21 9 1551 1564 22200938
  77. [95]Klika RJ Callahan KE Drum SN Individualized 12-week exercise training programs enhance aerobic capacity of cancer survivors Physician Sportsmed 2009 37 3 68 77 20048530
  78. [96]Spence RR Heesch KC Brown WJ Exercise and cancer rehabilitation: a systematic review Cancer Treat Rev 2010 36 2 185 194 19962830
  79. [97]Speed-Andrews AE Courneya KS Effects of exercise on quality of life and prognosis in cancer survivors Curr Sports Med Rep 2009 8 4 176 181 19584603
  80. [98]Wolf S Barton D Kottschade L Grothey A Loprinzi C Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies Eur J Cancer 2008 44 11 1507 1515 18571399
  81. [99]Beijers AJ Mols F Vreugdenhil G A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration Support Care Cancer 2014 22 7 1999 2007 24728618
  82. [100]Krishnan AV Goldstein D Friedlander M Kiernan MC Oxaliplatin-induced neurotoxicity and the development of neuropathy Muscle Nerve 2005 32 1 51 60 15880395
  83. [101]Ocean AJ Vahdat LT Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies Support Care Cancer 2004 12 9 619 625 15258838
  84. [102]Quasthoff S Hartung HP Chemotherapy-induced peripheral neuropathy J Neurol 2002 249 1 9 17 11954874
  85. [103]Mols F Beijers T Lemmens V van den Hurk CJ Vreugdenhil G van de Poll-Franse LV Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry J Clin Oncol 2013 31 21 2699 2707 23775951
  86. [104]Grothey A Oxaliplatin-safety profile: neurotoxicity Semin Oncol Nurs 2003 30 4 Suppl 15 5 13 14523789
  87. [105]Argyriou AA Bruna J Marmiroli P Cavaletti G Chemotherapy-induced peripheral neurotoxicity (CIPN): an update Crit Rev Oral Biol 2012 82 1 51 77 21908200
  88. [106]Hausheer FH Schilsky RL Bain S Berghorn EJ Lieberman F Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy Semin Oncol Nurs 2006 33 1 15 49 16473643
  89. [107]Park SB Goldstein D Krishnan AV Chemotherapy-induced peripheral neurotoxicity: a critical analysis CA Cancer J Clin 2013 63 6 419 437 24590861
  90. [109]Brouwers EE Huitema AD Boogerd W Beijnen JH Schellens JH Persistent neuropathy after treatment with cisplatin and oxaliplatin Acta Oncol 2009 48 6 832 841 19308757
  91. [110]Vatandoust S Joshi R Pittman KB A descriptive study of persistent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer Support Care Cancer 2014 22 2 513 518 24122404
  92. [111]Land SR Kopec JA Cecchini RS Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07 J Clin Oncol 2007 25 16 2205 2211 17470850
  93. [112]Smith EM Pang H Cirrincione C Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial JAMA 2013 309 13 1359 1367 23549581 PMC3912515
  94. [113]Choi M Craft B Geraci SA Surveillance and monitoring of adult cancer survivors Am J Med 2011 124 7 598 601 21683826
  95. [114]McMullen CK Hornbrook MC Grant M The greatest challenges reported by long-term colorectal cancer survivors with stomas J Support Oncol 2008 6 4 175 182 18491686
  96. [115]Danielsen AK Burcharth J Rosenberg J Patient education has a positive effect in patients with a stoma: a systematic review Colorectal Dis 2013 15 6 e276 e283 23470040
  97. [116]Schmidt-Hansen M Bennett MI Arnold S Bromham N Hilgart JS Oxycodone for cancer-related pain Cochrane Database Syst Rev 2015 2 CD003870 25723351
  98. [117]Negrini S Imperio G Villafane JH Negrini F Zaina F Systematic reviews of physical and rehabilitation medicine Cochrane contents. Part 1. Disabilities due to spinal disorders and pain syndromes in adults Eur J Phys Rehab Med 2013 49 4 597 609 24084418
  99. [118]Parry C Kent EE Mariotto AB Alfano CM Rowland JH Cancer survivors: a booming population Cancer Epidemiol Biomarkers Prev 2011 20 10 1996 2005 21980007 PMC3422885
  100. [120]Spanos CP Mamopoulos A Tsapas A Syrakos T Kiskinis D Female fertility and colorectal cancer Int J Colorectal Dis 2008 23 8 735 743 18458919
  101. [121]Elizur SE Tulandi T Meterissian S Huang JY Levin D Tan SL Fertility preservation for young women with rectal cancer--a combined approach from one referral center J Gastrointest Surg 2009 13 6 1111 1115 19224294
  102. [122]Hermann RM Henkel K Christiansen H Testicular dose and hormonal changes after radiotherapy of rectal cancer Radiother Oncol 2005 75 1 83 88 15878105
  103. [123]Cercek A Siegel CL Capanu M Reidy-Lagunes D Saltz LB Incidence of chemotherapy-induced amenorrhea in premenopausal women treated with adjuvant FOLFOX for colorectal cancer Clin Colorectal 2013 12 3 163 167 23871161
  104. [124]Ho VP Lee Y Stein SL Temple LK Sexual function after treatment for rectal cancer: a review Dis Colon Rectum 2011 54 1 113 125 21160322
  105. [125]Donovan KA Thompson LM Hoffe SE Sexual function in colorectal cancer survivors Cancer Control 2010 17 1 44 51 20010518
  106. [126]Downing A Morris EJ Richards M Health-related quality of life after colorectal cancer in England: a patient-reported outcomes study of individuals 12 to 36 months after diagnosis J Clin Oncol 2015 33 6 616 624 25559806
  107. [127]Den Oudsten BL Traa MJ Thong MS Higher prevalence of sexual dysfunction in colon and rectal cancer survivors compared with the normative population: a population-based study Eur J Cancer 2012 48 17 3161 3170 22608772
  108. [128]Lange MM Marijnen CA Maas CP Risk factors for sexual dysfunction after rectal cancer treatment Eur J Cancer 2009 45 9 1578 1588 19147343
  109. [129]Philip EJ Nelson C Temple L Psychological correlates of sexual dysfunction in female rectal and anal cancer survivors: analysis of baseline intervention data J Sex Med 2013 10 10 2539 2548 23551928 PMC3706574
  110. [130]Traa MJ Orsini RG Den Oudsten BL Measuring the health-related quality of life and sexual functioning of patients with rectal cancer: does type of treatment matter? Int J Cancer 2014 134 4 979 987 23934989
  111. [131]Ball M Nelson CJ Shuk E Men's experience with sexual dysfunction post-rectal cancer treatment: a qualitative study J Cancer Educ 2013 28 3 494 502 23821133 PMC3755110
  112. [132]Carter J Stabile C Seidel B Baseline characteristics and concerns of female cancer patients/survivors seeking treatment at a Female Sexual Medicine Program Support Care Cancer 2015 PMC4979074 25567673
  113. [133]Park SY Choi GS Park JS Kim HJ Park JA Choi JI Efficacy and safety of udenafil for the treatment of erectile dysfunction after total mesorectal excision of rectal cancer: a randomized, double-blind, placebo-controlled trial Surgery 2015 157 1 64 71 25482466
  114. [134]Sturdee DW Panay N International Menopause Society Writing G Recommendations for the management of postmenopausal vaginal atrophy Climacteric 2010 13 6 509 522 20883118
  115. [135]Averyt JC Nishimoto PW Addressing sexual dysfunction in colorectal cancer survivorship care J Gastrointest Oncol 2014 5 5 388 394 25276411 PMC4173048
  116. [136]Korolija D Sauerland S Wood-Dauphinee S Evaluation of quality of life after laparoscopic surgery: evidence-based guidelines of the European Association for Endoscopic Surgery Surg Endosc 2004 18 6 879 897 15108103
  117. [137]Liu L Herrinton LJ Hornbrook MC Wendel CS Grant M Krouse RS Early and late complications among long-term colorectal cancer survivors with ostomy or anastomosis Dis Colon Rectum 2010 53 2 200 212 20087096 PMC3320086
  118. [138]Delacroix SE Jr Winters JC Voiding dysfunction after pelvic colorectal surgery Clin Colon Rectal Surg 2010 23 2 119 127 21629630 PMC2967332
  119. [139]Panjari M Bell RJ Burney S Bell S McMurrick PJ Davis SR Sexual function, incontinence, and wellbeing in women after rectal cancer--a review of the evidence J Sex Med 2012 9 11 2749 2758 22905761
  120. [140]Lange MM van de Velde CJ Faecal and urinary incontinence after multimodality treatment of rectal cancer PLoS Med 2008 5 10 e202 18842066 PMC2561075
  121. [142]Sinicrope FA Foster NR Yothers G Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy Cancer 2013 119 8 1528 1536 23310947 PMC3769640
  122. [143]Gibson TM Park Y Robien K Body mass index and risk of second obesity-associated cancers after colorectal cancer: a pooled analysis of prospective cohort studies J Clin Oncol 2014 32 35 4004 4011 25267739 PMC4251963
  123. [144]Dignam JJ Polite BN Yothers G Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer J Natl Cancer Inst 2006 98 22 1647 1654 17105987
  124. [145]Meyerhardt JA Niedzwiecki D Hollis D Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803 J Clin Oncol 2008 26 25 4109 4115 18757324 PMC2654367
  125. [146]Schmid D Leitzmann MF Association between physical activity and mortality among breast cancer and colorectal cancer survivors: a systematic review and meta-analysis Ann Oncol 2014 25 7 1293 1311 24644304
  126. [147]Meyerhardt JA Sato K Niedzwiecki D Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803 J Natl Cancer Inst 2012 104 22 1702 1711 23136358 PMC3502194
  127. [148]Meyerhardt JA Niedzwiecki D Hollis D Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer JAMA 2007 298 7 754 764 17699009
  128. [151]Yang B Jacobs EJ Gapstur SM Stevens V Campbell PT Active smoking and mortality among colorectal cancer survivors: the Cancer Prevention Study II nutrition cohort J Clin Oncol 2015 33 8 885 893 25646196
  129. [153]Westmaas JL Alcaraz KI Berg CJ Stein KD Prevalence and correlates of smoking and cessation-related behavior among survivors of ten cancers: findings from a nationwide survey nine years after diagnosis Cancer Epidemiol Biomarkers Prev 2014 23 9 1783 1792 25100826
  130. [154]Mayer DK Birken SA Check DK Chen RC Summing it up: an integrative review of studies of cancer survivorship care plans (2006–2013) Cancer 2015 121 7 978 996 25252164 PMC4948720

Cited by

Sorted by citations

Authors
El‐Shami, K., Oeffinger, K. C., Erb, N. L., Willis, A., Bretsch, J. K., Pratt‐Chapman, M. L., Cannady, R. S., Wong, S. L., Rose, J., Barbour, A. L., Stein, K. D., Sharpe, K. B., Brooks, D. D., & Cowens‐Alvarado, R. L.
Venue
CA: A Cancer Journal for Clinicians
Publisher
Wiley
Published
2015-09-08
Volume
65
Issue
6
Pages
427-455
ISSN
  • 0007-9235
  • 1542-4863
DOI
10.3322/caac.21286
PMC
PMC5385892
Cited by
327
References
15
Language
en
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review